Olfactory Neuron Prokineticin-2 as a Potential Target in Parkinson's Disease.
Journal
Annals of neurology
ISSN: 1531-8249
Titre abrégé: Ann Neurol
Pays: United States
ID NLM: 7707449
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
05
10
2022
received:
16
07
2022
accepted:
06
10
2022
pubmed:
12
10
2022
medline:
12
1
2023
entrez:
11
10
2022
Statut:
ppublish
Résumé
The objective of this study was to outline the dynamics of prokineticin-2 pathway in relation to clinical-pathological features of Parkinson's disease by examining olfactory neurons of patients. Thirty-eight patients (26 de novo, newly diagnosed) and 31 sex/age-matched healthy controls underwent noninvasive mucosa brushing for olfactory neurons collection, and standard clinical assessment. Gene expression levels of prokineticin-2, prokineticin-2 receptors type 1 and 2, and prokineticin-2-long peptide were measured in olfactory neurons by real-time polymerase chain reaction (PCR); moreover, the prokineticin-2 protein and α-synuclein species (total and oligomeric) were quantified by immunofluorescence staining. Prokineticin-2 expression was significantly increased in Parkinson's disease. De novo patients had higher prokineticin-2 levels, directly correlated with Movement Disorder Society-Sponsored Revision of the Unified Parkinson Disease Rating Scale (MDS-UPDRS) part III motor score. In addition, oligomeric α-synuclein was higher in Parkinson's disease and directly correlated with prokineticin-2 protein levels. Total α-synuclein did not differ between patients and controls. Prokineticin-2 is a chemokine showing neuroprotective effects in experimental models of Parkinson's disease, but translational proof of its role in patients is still lacking. Here, we used olfactory neurons as the ideal tissue to analyze molecular stages of neurodegeneration in vivo, providing unprecedented evidence that the prokineticin-2 pathway is activated in patients with Parkinson's disease. Specifically, prokineticin-2 expression in olfactory neurons was higher at early disease stages, proportional to motor severity, and associated with oligomeric α-synuclein accumulation. These data, consistently with preclinical findings, support prokineticin-2 as a candidate target in Parkinson's disease, and validate reliability of olfactory neurons to reflect pathological changes of the disease. ANN NEUROL 2023;93:196-204.
Substances chimiques
alpha-Synuclein
0
PROK2 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
196-204Informations de copyright
© 2022 American Neurological Association.
Références
Petrillo S, Schirinzi T, Di Lazzaro G, et al. Systemic activation of Nrf2 pathway in Parkinson's disease. Mov Disord 2020;35:180-184. https://doi.org/10.1002/mds.27878.
Schirinzi T, Sancesario GM, Di Lazzaro G, et al. CSF α-synuclein inversely correlates with non-motor symptoms in a cohort of PD patients. Parkinsonism Relat Disord 2018;61:203-206.
Lang AE, Espay AJ. Disease modification in Parkinson's disease: current approaches, challenges, and future considerations. Mov Disord 2018;33:660-677.
Espay AJ. Movement disorders research in 2021: cracking the paradigm. Lancet Neurol 2022;21:10-11.
Krashia P, Cordella A, Nobili A, et al. Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson's disease. Nat Commun 2019;10:3945.
Borghammer P. How does parkinson's disease begin? Perspectives on neuroanatomical pathways, prions, and histology. Mov Disord 2018;33:48-57.
Rey NL, Wesson DW, Brundin P. The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases. Neurobiol Dis 2018;109:226-248.
Braak H, Ghebremedhin E, Rüb U, et al. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004;318:121-134.
Stefani A, Iranzo A, Holzknecht E, et al. Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder. Brain 2021;144:1118-1126.
Brozzetti L, Sacchetto L, Cecchini MP, et al. Neurodegeneration-associated proteins in human olfactory neurons collected by nasal brushing. Front Neurosci 2020;14:145.
Negri L, Ferrara N. The prokineticins: neuromodulators and mediators of inflammation and myeloid cell-dependent angiogenesis. Physiol Rev 2018;98:1055-1082.
Lattanzi R, Miele R. Prokineticin-receptor network: mechanisms of regulation. Life 2022;12:172.
Schirinzi T, Maftei D, Pieri M, et al. Increase of Prokineticin-2 in serum of patients with Parkinson's disease. Mov Disord 2021;36:1031-1033. https://doi.org/10.1002/mds.28458.
Maftei D, Schirinzi T, Mercuri NB, et al. Potential clinical role of Prokineticin 2 (PK2) in neurodegenerative diseases. Curr Neuropharmacol 2022;20:2019-2023.
Lattanzi R, Severini C, Maftei D, et al. The role of prokineticin 2 in oxidative stress and in neuropathological processes. Front Pharmacol 2021;12:640441.
Lattanzi R, Maftei D, Negri L, et al. PK2β ligand, a splice variant of prokineticin 2, is able to modulate and drive signaling through PKR1 receptor. Neuropeptides 2018;71:32-42.
Lattanzi R, Maftei D, Petrella C, et al. Involvement of the chemokine prokineticin-2 (PROK2) in Alzheimer's disease: from animal models to the human pathology. Cell 2019;8:1430.
Gordon R, Neal ML, Luo J, et al. Prokineticin-2 upregulation during neuronal injury mediates a compensatory protective response against dopaminergic neuronal degeneration. Nat Commun 2016;7:1-18.
Orrú CD, Bongianni M, Tonoli G, et al. A test for Creutzfeldt-Jakob disease using nasal brushings. N Engl J Med 2014;371:519-529. https://doi.org/10.1056/nejmoa1315200.
Sengupta U, Guerrero-Muñoz MJ, Castillo-Carranza DL, et al. Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies. [Internet]. Biol Psychiatry 2015;78:672-683.
Neal M, Luo J, Harischandra DS, et al. Prokineticin-2 promotes chemotaxis and alternative A2 reactivity of astrocytes. Glia 2018;66:2137-2157.
Blesa J, Trigo-Damas I, Dileone M, et al. Compensatory mechanisms in Parkinson's disease: circuits adaptations and role in disease modification. Exp Neurol 2017;298:148-161.
Yan Y, Jiang W, Liu L, et al. Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome. Cell 2015;160:62-73.
Korshunov KS, Blakemore LJ, Trombley PQ. Illuminating and sniffing out the Neuromodulatory roles of dopamine in the retina and olfactory bulb. Front Cell Neurosci 2020;14:275.
Severini C, Lattanzi R, Maftei D, et al. Bv8/prokineticin 2 is involved in Aβ-induced neurotoxicity. Sci. Rep. 2015;5:15301.
Ingelsson M. Alpha-synuclein oligomers-neurotoxic molecules in Parkinson's disease and other lewy body disorders. Front Neurosci 2016;10:408.
Saito Y, Shioya A, Sano T, et al. Lewy body pathology involves the olfactory cells in Parkinson's disease and related disorders. Mov. Disord. 2016;31:135-138.
Stevenson TJ, Murray HC, Turner C, et al. α-synuclein inclusions are abundant in non-neuronal cells in the anterior olfactory nucleus of the Parkinson's disease olfactory bulb. Sci Rep 2020;10:6682.
Parnetti L, Gaetani L, Eusebi P, et al. CSF and blood biomarkers for Parkinson's disease. Lancet Neurol 2019;18:573-586.
Parnetti L, Cicognola C, Eusebi P, Chiasserini D. Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis. Biomark Med 2016;10:35-49.
Duda JE, Shah U, Arnold SE, et al. The expression of α-, β-, and γ-synucleins in olfactory mucosa from patients with and without neurodegenerative diseases. Exp Neurol 1999;160:515-522.
Bao Z, Liu Y, Chen B, et al. Prokineticin-2 prevents neuronal cell deaths in a model of traumatic brain injury. Nat Commun 2021;12:4220.
Yang Z, Wang M, Zhang Y, et al. Metformin ameliorates diabetic cardiomyopathy by activating the PK2/PKR pathway. Front Physiol 2020;11:425. https://doi.org/10.3389/fphys.2020.00425/full.